

Special Issue

Biomarkers for Neurodegenerative Disorders: From Bench to Bedside

Message from the Guest Editor

Our knowledge on neurodegenerative disorders is rapidly expanding. Molecular, neuropsychological and imaging markers are valuable tools to understand the various mechanisms underlying these disorders. In addition, such biomarkers may be of clinical value, and some of them have been incorporated in diagnostic criteria and guidelines for neurodegenerative disorders. This Special Issue provides insights into the use of biomarkers in neurodegenerative disorders, including (but not limited to) Alzheimer's disease, frontotemporal dementias, Lewy body dementia, Parkinson's disease, atypical parkinsonian disorders and amyotrophic lateral sclerosis. Among others, fluid biomarkers (cerebrospinal fluid or blood), structural imaging biomarkers (atrophy), positron emission tomography (PET) biomarkers (amyloid- and/or tau-PET and others) and genetic biomarkers are especially important. Papers on biomarkers related to basic mechanisms are welcome, but the main interest is on clinically meaningful biomarkers, their help in the diagnosis of patients with cognitive and movement disorders, and in selecting patients for newer or emerging treatments.

Guest Editor

Dr. George P. Paraskevas

2nd Department of Neurology, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece

Deadline for manuscript submissions

30 April 2025



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 5.2
Indexed in PubMed



mdpi.com/si/201949

Biomedicines
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 5.2
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 15.3 days after submission; acceptance to publication is undertaken in 3.4 days (median values for papers published in this journal in the first half of 2024).